Gradient Denervation Technologies, a Paris, France-based medical device company for the treatment of pulmonary hypertension, raised €14M in Series A funding.
The round was led by Asabys Partners through its new fund Sabadell Asabys II and was joined by Thuja Capital and Sofinnova Partners.
The company intends to use the funds to support ongoing clinical development and evaluation of its ultrasound-based catheter device.
Led by CEO Martin Grasse, Gradient Denervation Technologies has developed a minimally invasive device for the treatment of pulmonary hypertension, which leverages intellectual property developed at Stanford University and has been incubated since 2020 by Sofinnova MD Start, a Paris-based medtech accelerator that works with clinicians and entrepreneurs to develop disruptive medical devices. The Gradient device – founded on innovation developed by the clinicians Dr. Swaminadhan Gnanashanmugam and Dr. Jeffrey Feinstein at the Stanford Biodesign Program – is for investigational use only and is not approved for commercial use.
The company’s initial focus is the Group 2 pulmonary hypertension patient population, which consists of patients with heart failure and associated high pulmonary vascular resistance.
FinSMEs
07/09/2023